StartupLinkno
StartupsInvestorerNettverkBloggRegistrer selskap
StartupLink — katalogen over norske startups© 2026 StartupLink

Norske startups

251treff i katalogen

Filtre
Bransje1›
Sted›
Ansatte›
Fase›
Marked›
Forretningsmodell›
Siste runde›
Status›
Filtre
Filtre
Bransje1›
Sted›
Ansatte›
Fase›
Marked›
Forretningsmodell›
Siste runde›
Status›

4 PHASES AS

Oslo

Premier Provider of Clinical Trial Software for Pharmaceutical Industry

ProgramvareHelseTidlig faseB2B
Team 2–10 ansatte

Abel Technologies

Tromsø

A healthcare center that provides health advisory services to trainers, physiotherapists, and nutritionists

Helse
Vekstfase
B2B
Hentet $238K+60 %

Actithera

Oslo

Radioligand therapies for targeted cancer treatment, utilizing a proprietary chemistry platform for prolonged tumor retention and preservation of healthy tissue

HelseVekstfaseB2B
Hentet $75.5M

Adjutec Pharma

Oslo

Dedicated to developing and providing novel antibiotic resistance breakers to the global market

HelseTidlig faseB2B
Hentet $3.8K-11 %

Age Labs

Oslo

Discovers, develops, and commercializes diagnostic tests for the early detection of age-related diseases

HelseTidlig faseB2B
Hentet $2.4M+125 %

Agiana Pharmaceuticals

Oslo

Novel anti-arrhythmic therapy for cardiac rhythm management

HelseTidlig faseB2B
Team 2–10 ansatte

Agilera Pharma

Oppkjøpt

Lillestrøm

HelseTidlig faseB2B
Vekst 12 mnd +21 %

Aidee

Bærum

A health tech company which aims to change the way people measure health and diagnose patients

HelseTidlig faseB2B
Hentet $1.3M

Aiveo AS

Grimstad

HelseTidlig faseB2B
Hentet $12.1K+50 %

Akigai

Oslo

Repurposed oncology drugs for neuropathic pain treatment

HelseTidlig faseB2B
Hentet $4M+43 %

Alfred Surgery

Norge

Improving safety in surgery through structured education and standardization

UtdanningHelseTidlig faseB2B

AlgaePro

Bergen

Set out to save the world by producing highly nutritious micro algae in nature’s own way

Mat og drikkeHelseTidlig faseB2B
Hentet $12.1K-50 %

Alv B

Oslo

Develops immunotherapy, as well as other experimental cancer therapeutics for dogs and cats

HelseTidlig faseB2B
Hentet $84.7K-45 %

Ambr Institute

Oslo

Medical platform leveraging explainable AI for personalized chronic disease prevention and management

HelseTidlig faseB2B
Team 11–50 ansatte

Amino

Oslo

Preventive health checks with personalized doctor analysis

HelseTidlig faseB2C
Hentet $968K
A

Angenovo

Lav aktivitet

Indre Østfold

HelseTidlig faseB2B

Antigrade

Oslo

A biotechnology company

HelseTidlig faseB2B
Hentet $18.2K-11 %

ARCTIC PHARMA AS

Oslo

Developing first in class cancer therapy blocking the energy supply for cancer growth

HelseTidlig faseB2B
Team 2–10 ansatte

ARTBIO

Cambridge, United States

A clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART)

HelseSen faseB2B
Hentet $245M+11 %

Arxx Therapeutics

Oslo

Develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis

HelseTidlig faseB2B
Hentet $387K

Askin

Nordre Follo

Skin specialists that help people of all ages, from newborns to the elderly, with everything from simple skin changes to serious disorders

HelseVelværeTidlig faseB2C
Hentet $2.4M

Attent AS

Oslo

AI-driven future of dental health

HelseTidlig faseB2C
Team 1 ansatt

Augere Medical

Oslo

A startup with a dedicated team of medical doctors, computer scientists and business developers, working to bring cutting-edge AI to medical devices

HelseTidlig faseB2B
Hentet $4M-61 %
A

Aura Biopharm

Norge

Aura Biopharm – A new opportunity for health

HelseTidlig faseB2B
← ForrigeSide 1 av 11Neste →